Dissolving Effects of Cicer Arietinum on Renal and ureteral Stones

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 70

Inclusion Criteria

Inclusion Criteria: Renal or ureteral stone diagnosis with size between 6 to 10 millimeter by urologist in any composition and using sonography, K.U.B and/or C.T scan(without contrast); Age between 18 to 50 in both genders; Patient should not be affected by any grade of hydronephrosis; Anatomical position of stones in renal pelvis, calyxes, upper-middle-lower portion of ureter; Controllable pain, nausea and vomiting by oral NSAIDS and oral anti emetics; Intending to participation in study, inform consent and signing it's written form before recruiting in the study; Not consumption any chemical or herbal drug at least one month before entering the study; Not consumption the nephrolithogen drugs; Normal range of renal function tests(BUN, Cr); Normal range of liver function tests(SGPT, SGOT, Alk Phos); Absence any symptom and sign of urinary tract infection.
Exclusion criteria: Patients with renal or ureteral stone/s less than 5 mm or more than 11 mm in size; Affecting by urinary stone complications(any grade of hydronephrosis and U.T.I); Patients who need to surgery, other procedures or emergency interventions; Uncontrolled pain, nausea and vomiting despite using oral NSAIDS and oral anti emetics; Consumption other types of chemical or herbal drugs except those prescribed in this study; Subjects intending to withdraw at any time during the course of study; Having a history of significant problems(diabetes mellitus, renal dysfunctions, hepatic dysfunctions and peptic ulcer); Pregnancy; Lactating.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in size of stone/s. Timepoint: before intervention and just after termination of intervention. Method of measurement: in millimeter by using ruler (visual).

Secondary Outcome Measures

Name	Time	Method
Change in plasma concentration of BUN ? Creatinine ? ALT? AST. Timepoint: before intervention and just after termination of intervention. Method of measurement: mg/dl for BUN and Creatinine , u/lit for AST and ALT.